Drugs /

gallium ga 68-dotatate

Back to Drugs List

Overview

NCI Definition [1]:
A radioconjugate consisting of the somatostatin analogue tyrosine-3-octreotate (Tyr3-octreotate or TATE) labeled with the positron emission tomography (PET) tracer gallium Ga 68 via the macrocyclic chelating agent dodecanetetraacetic acid (DOTA), which may be used as a somatostatin receptor (SSTR) imaging agent in conjunction with PET to image neuroendocrine tumors (NETs). Gallium Ga 68-DOTATATE binds to SSTRs, with a much higher affinity for type 2 SSTR, present on the cell membranes of many types of NETs. This allows for visualization of SSTR-positive cells upon imaging. SSTR subtypes have been shown to be present in large numbers on NETs and their metastases, while most other normal tissues express low levels of SSTR subtypes.

Clinical Trials

View Clinical Trials for gallium ga 68-dotatate

Gallium ga 68-dotatate has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating gallium ga 68-dotatate, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

SSTR1 Expression, SSTR2 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for gallium ga 68-dotatate clinical trials.

Gastrointestinal neuroendocrine tumors, meningioma, and pancreatic neuroendocrine tumor are the most common diseases being investigated in gallium ga 68-dotatate clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Gallium Ga 68-Dotatate
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating gallium ga 68-dotatate and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gallium 68 dota-octreotide, gallium-68 dota-dphe1, tyr3-octreotate, gallium-68 dota-dphe1, tyr3-octreotate, (68)ga-dota-tate, 68gallium-dota-tyr(3)-thr(8)-octreotate, 68ga-dotatate
NCIT ID [1]:
C97661

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.